A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen. (VIKING-3)
A Phase III Study to Demonstrate the Antiviral Activity and Safety of Dolutegravir in HIV-1 Infected Adult Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
Sponsor: GlaxoSmithKline
A PHASE3 clinical study on Infection, Human Immunodeficiency Virus, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 7 data snapshots since 2011. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
May 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
- Shionogi
- ViiV Healthcare
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Albany, United States , Alicante, Spain , Amadora, Portugal , Annandale, United States , Atlanta, United States , Augusta, United States , Aulnay-sous-Bois, France , Austin, United States , Badalona, Spain and 55 more locations